España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Sarepta Therapeutics
SRPT
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$113.13
2.27
2.05%
Pre-Market: 9:03 AM EDT
Get Report
Comment
Sarepta Therapeutics (SRPT) Forecast
News
Earnings
Sarepta Therapeutics (SRPT) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Government Trades
Short Interest
Latest news for Sarepta Therapeutics (NASDAQ:SRPT) Stock
Sarepta Therapeutics Stock (NASDAQ: SRPT)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, November 07, 2024
Guggenheim Maintains Buy on Sarepta Therapeut...
Benzinga Newsdesk
Baird Maintains Outperform on Sarepta Therape...
Benzinga Newsdesk
Evercore ISI Group Maintains Outperform on Sa...
Benzinga Newsdesk
Sarepta Therapeutics To Rally Around 30%? Here Are 10 Top Analyst Forecasts For Thursday
Avi Kapoor
Sarepta Therapeutics shares are trading highe...
Benzinga Newsdesk
This McKesson Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Avi Kapoor
Cantor Fitzgerald Upgrades Sarepta Therapeuti...
Benzinga Newsdesk
Needham Reiterates Buy on Sarepta Therapeutic...
Benzinga Newsdesk
Wednesday, November 06, 2024
Sarepta Therapeutics shares are trading lower...
Benzinga Newsdesk
Sarepta Therapeutics Q3 2024 Adj. EPS $0.62 B...
Benzinga Newsdesk
Monday, October 21, 2024
Peeling Back The Layers: Exploring Sarepta Therapeutics Through Analyst Insights
Benzinga Insights
RBC Capital Reiterates Outperform on Sarepta ...
Benzinga Newsdesk
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Avi Kapoor
Unveiling 15 Analyst Insights On Sarepta Therapeutics
Benzinga Insights
Jefferies Initiates Coverage On Sarepta Thera...
Benzinga Newsdesk
Friday, October 18, 2024
After US Senator, Unions Urge Federal Trade Commission To Block Novo's $16.5B Acquisition Of Catalent
Vandana Singh
Monday, October 14, 2024
Needham Reiterates Buy on Sarepta Therapeutic...
Benzinga Newsdesk
Thursday, October 10, 2024
Sarepta Therapeutics shares are trading highe...
Benzinga Newsdesk
Raymond James Reinstates Outperform on Sarept...
Benzinga Newsdesk
Friday, October 04, 2024
Analyst Scoreboard: 12 Ratings For Sarepta Therapeutics
Benzinga Insights
RBC Capital Maintains Outperform on Sarepta T...
Benzinga Newsdesk
Tuesday, October 01, 2024
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
MarketBeat
Thursday, September 26, 2024
Sarepta Therapeutics To Present New Data From...
Benzinga Newsdesk
Friday, September 20, 2024
Cantor Fitzgerald Reiterates Neutral on Sarep...
Benzinga Newsdesk
Thursday, September 19, 2024
RBC Capital Reiterates Outperform on Sarepta ...
Benzinga Newsdesk
Wednesday, September 18, 2024
10 Health Care Stocks With Whale Alerts In Today's Session
Benzinga Insights
Friday, September 06, 2024
Unveiling 26 Analyst Insights On Sarepta Therapeutics
Benzinga Insights
RBC Capital Reiterates Outperform on Sarepta ...
Benzinga Newsdesk
Tuesday, September 03, 2024
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
Vandana Singh
Friday, August 16, 2024
How Is The Market Feeling About Sarepta Therapeutics?
Benzinga Insights
Thursday, August 15, 2024
A Closer Look at 28 Analyst Recommendations For Sarepta Therapeutics
Benzinga Insights
RBC Capital Reiterates Outperform on Sarepta ...
Benzinga Newsdesk
Monday, August 12, 2024
$100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today
Benzinga Insights
Sunday, August 11, 2024
Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio?
Lekha Gupta
Friday, August 09, 2024
Sarepta Therapeutics shares are trading lower...
Benzinga Newsdesk
Thursday, August 08, 2024
RBC Capital Maintains Outperform on Sarepta T...
Benzinga Newsdesk
Smart Money Is Betting Big In SRPT Options
Benzinga Insights
Citigroup Maintains Neutral on Sarepta Therap...
Benzinga Newsdesk
Cantor Fitzgerald Maintains Neutral on Sarept...
Benzinga Newsdesk
Evercore ISI Group Upgrades Sarepta Therapeut...
Benzinga Newsdesk
Barclays Maintains Overweight on Sarepta Ther...
Benzinga Newsdesk
McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Avi Kapoor
Sarepta Therapeutics shares are trading lower...
Benzinga Newsdesk
Piper Sandler Maintains Overweight on Sarepta...
Benzinga Newsdesk
Wednesday, August 07, 2024
Sarepta Therapeutics Sees FY25 Net Product Re...
Benzinga Newsdesk
Sarepta Therapeutics shares are trading lower...
Benzinga Newsdesk
Sarepta Therapeutics Q2 2024 Adj. EPS $0.44 B...
Benzinga Newsdesk
Monday, July 29, 2024
26 Analysts Have This To Say About Sarepta Therapeutics
Benzinga Insights
RBC Capital Upgrades Sarepta Therapeutics to ...
Benzinga Newsdesk
Thursday, July 18, 2024
Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today
Benzinga Insights
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch